Zhejiang Jingxin Pharmaceutical Co., Ltd. (SHE: 002020)

Zhejiang Jingxin Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Operating Revenue	4,139	3,920	3,717	3,401	3,214	3,604
Other Revenue	73.67	78.89	62.81	65.06	44.25	42.23
Revenue	4,212	3,999	3,780	3,467	3,258	3,647
Revenue Growth (YoY)	9.59%	5.79%	9.04%	6.40%	-10.66%	23.88%
Cost of Revenue	2,072	1,988	1,774	1,547	1,277	1,282
Gross Profit	2,140	2,011	2,006	1,920	1,981	2,364
Selling, General & Admin	1,021	994.61	984.94	970.72	1,178	1,588
Research & Development	426.68	400.79	367.04	334.14	257.91	252.58
Other Operating Expenses	51.94	30.09	36.19	26.57	28.02	35.39
Operating Expenses	1,515	1,432	1,392	1,342	1,462	1,878
Operating Income	625.25	579.08	613.8	577.8	519.31	486
Interest Expense	-8.92	-7.31	-6.01	-4.97	-6	-10.61
Interest & Investment Income	71.77	66.71	85.05	96.29	79.73	88.75
Currency Exchange Gain (Loss)	-1.07	3.43	14.43	-3.84	-9.77	1.75
Other Non Operating Income (Expenses)	-1.35	-0.97	-3.21	-7.19	-9.77	-1.73
EBT Excluding Unusual Items	685.68	640.94	704.06	658.09	573.49	564.16
Impairment of Goodwill	-	-	-	-	-	-1.6
Gain (Loss) on Sale of Investments	24.16	24.44	10.15	7.23	131.49	1.59
Gain (Loss) on Sale of Assets	2.77	6.86	0.61	-0.48	-0.04	-2.07
Asset Writedown	-0.02	-0.01	-0.07	-8.42	-0.51	-0.74
Other Unusual Items	110.58	35.81	35.56	43.12	54.54	42.08
Pretax Income	823.18	708.04	750.32	699.54	758.98	603.41
Income Tax Expense	112.34	84.62	82.49	81.57	105.65	81.47
Earnings From Continuing Operations	710.84	623.42	667.82	617.96	653.33	521.95
Minority Interest in Earnings	-5.74	-4.52	-5.57	-5.42	-0.26	-1.55
Net Income	705.1	618.9	662.25	612.54	653.07	520.4
Net Income to Common	705.1	618.9	662.25	612.54	653.07	520.4
Net Income Growth	3.52%	-6.55%	8.12%	-6.21%	25.49%	40.92%
Shares Outstanding (Basic)	860	860	860	817	796	855
Shares Outstanding (Diluted)	860	860	860	817	796	855
Shares Change (YoY)	-0.25%	-0.06%	5.31%	2.55%	-6.90%	-1.28%
EPS (Basic)	0.82	0.72	0.77	0.75	0.82	0.61
EPS (Diluted)	0.82	0.72	0.77	0.75	0.82	0.61
EPS Growth	3.78%	-6.49%	2.67%	-8.54%	34.80%	42.86%
Free Cash Flow	546.26	273.32	340.2	-33.37	179.21	197.97
Free Cash Flow Per Share	0.63	0.32	0.40	-0.04	0.23	0.23
Dividend Per Share	0.300	0.300	0.300	0.300	0.292	0.292
Dividend Growth	0%	0%	0%	2.85%	0%	16.68%
Gross Margin	50.81%	50.30%	53.06%	55.39%	60.80%	64.84%
Operating Margin	14.84%	14.48%	16.24%	16.67%	15.94%	13.33%
Profit Margin	16.74%	15.48%	17.52%	17.67%	20.04%	14.27%
Free Cash Flow Margin	12.97%	6.84%	9.00%	-0.96%	5.50%	5.43%
EBITDA	865.36	778.68	766.56	713.89	642.51	592.21
EBITDA Margin	20.54%	19.47%	20.28%	20.59%	19.72%	16.24%
D&A For EBITDA	240.1	199.6	152.76	136.09	123.2	106.21
EBIT	625.25	579.08	613.8	577.8	519.31	486
EBIT Margin	14.84%	14.48%	16.24%	16.67%	15.94%	13.33%
Effective Tax Rate	13.65%	11.95%	10.99%	11.66%	13.92%	13.50%
Revenue as Reported	4,212	3,999	3,780	3,467	3,258	3,647
Advertising Expenses	-	-	-	5.13	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.